---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-110681"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:57:54.982031+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reports FY2025 net loss of $35.2M; $40M private placement extends runway into 2029

## Summary
- Net loss for FY2025 was $35.2 million, compared to $51.3 million in FY2024.
- Cash and investments at Dec 31, 2025: $60.0 million; private placement in March 2026 added ~$40 million gross.
- Phase 2 study of oral epetraborole in polycythemia vera to begin 3Q26; data readouts possible from 4Q26.
- Phase 2 investigator-initiated trial in M. abscessus lung disease enrollment expected 1Q26; topline late 2027.
- Phase 1 first-in-human trial of AN2-502998 for Chagas nearing completion; initial data expected 1Q26.

## SEC filing metadata
- accession: 0001193125-26-110681
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312526110681/0001193125-26-110681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312526110681/antx-20260317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-110681
- JSON: https://secwatch.observer/filing/0001193125-26-110681.json
- Plain text: https://secwatch.observer/filing/0001193125-26-110681.txt

## Key facts
- Earnings Releases
  AN2 Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2025.
  - Period: fourth quarter and year ended December 31, 2025
  - Result: reported results
  source text: On March 17, 2026, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312526110681/0001193125-26-110681-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.